Skip to content

Study · Non-randomized trial · n = 10 · 2003

4 results

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes.

Egan JM, Meneilly GS, Elahi D

American journal of physiology. Endocrinology and metabolism10 Dec 2002Cited by 62 (Europe PMC)

PMID12475750 (opens in a new tab)DOI10.1152/ajpendo.00315.2002 (opens in a new tab)PepBankPUB-12475750
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In insulin-naive patients with type 2 diabetes, exendin‑4 reduced bedtime capillary glucose from 15.5 to 9.2 mmol/l.

    In plain wordsIn insulin-naive patients with type 2 diabetes, bedtime glucose fell after exendin‑4 treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBedtime capillary glucose
    Study

    n = 10

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 1 moAs given in this study (human).

    Measurements

    Bedtime capillary blood glucose
    15.5 mmol/l
    before treatment
    Bedtime capillary blood glucose
    9.2 mmol/l
    after 1 month of treatment

    Source sentences

    Summary
    The greatest decline in capillary blood glucose was seen before bed, with a drop from 15.5 to 9.2 mmol/l (P < 0.0001).
    1 context sentence
    Summary · context
    Ten patients aged 44-72 yr with mean fasting glucose levels of 11.4 +/- 0.9 mmol/l were enrolled, and daily or twice-daily bolus subcutaneous exendin-4 was self-administered for 1 mo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In insulin-naive patients with type 2 diabetes, exendin‑4 reduced glycosylated hemoglobin from 9.1 to 8.3%.

    In plain wordsIn insulin-naive patients with type 2 diabetes, glycosylated hemoglobin fell after exendin‑4 treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlycosylated hemoglobin
    Study

    n = 10

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 1 moAs given in this study (human).

    Measurements

    Glycosylated hemoglobin
    9.1%
    before treatment
    Glycosylated hemoglobin
    8.3%
    after 1 month of treatment

    Source sentences

    Summary
    Glycosylated hemoglobin improved significantly with treatment, from 9.1 to 8.3% (P = 0.009).
    1 context sentence
    Summary · context
    Ten patients aged 44-72 yr with mean fasting glucose levels of 11.4 +/- 0.9 mmol/l were enrolled, and daily or twice-daily bolus subcutaneous exendin-4 was self-administered for 1 mo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In insulin-naive patients with type 2 diabetes, exendin‑4 improved beta-cell glucose sensitivity measured with C-peptide during a hyperglycemic clamp.

    In plain wordsIn insulin-naive patients with type 2 diabetes, beta-cell glucose sensitivity improved after exendin‑4 treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeta-cell glucose sensitivity
    Study

    n = 10

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 1 moAs given in this study (human).

    Source sentences

    Summary
    beta-Cell sensitivity to glucose was improved, as assessed by C-peptide levels during a hyperglycemic clamp.
    1 context sentence
    Summary · context
    Ten patients aged 44-72 yr with mean fasting glucose levels of 11.4 +/- 0.9 mmol/l were enrolled, and daily or twice-daily bolus subcutaneous exendin-4 was self-administered for 1 mo.
  4. 04HumanNon-randomized trialSafety outcome

    In insulin-naive patients with type 2 diabetes, no significant adverse effects were noted or reported during exendin‑4 treatment.

    In plain wordsIn insulin-naive patients with type 2 diabetes, no significant adverse effects were reported during exendin‑4 treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSignificant adverse effects
    Study

    n = 10

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneous · 1 moAs given in this study (human).

    Source sentences

    Summary
    No significant adverse effects were noted or reported.
    1 context sentence
    Summary · context
    Ten patients aged 44-72 yr with mean fasting glucose levels of 11.4 +/- 0.9 mmol/l were enrolled, and daily or twice-daily bolus subcutaneous exendin-4 was self-administered for 1 mo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.